LFST (LifeStance Health Group) NonCurrent Deferred Revenue: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LFST LifeStance Health Group Inc LFST
54 GF Score
Price $10.83
GF Value $8.46
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is LifeStance Health Group NonCurrent Deferred Revenue?

LifeStance Health Group LFST +1.88% 54 NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus rates LFST with a GF Score™ of 54/100 and a GF Value™ of $8.46 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

LifeStance Health Group's non-current deferred revenue for the quarter that ended in Jun. 2026 was $0 Mil.

LifeStance Health Group NonCurrent Deferred Revenue Related Terms

LifeStance Health Group NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for LifeStance Health Group's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeStance Health Group NonCurrent Deferred Revenue Chart

LifeStance Health Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

LifeStance Health Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LFST
54GF Score
LifeStance Health Group Inc LFST
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $0 Mil mean?
LifeStance Health Group (LFST) has a NonCurrent Deferred Revenue of $0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on LifeStance Health Group and its competitors.
Is LifeStance Health Group's NonCurrent Deferred Revenue too high?
LifeStance Health Group's current NonCurrent Deferred Revenue is $0 Mil. Overall, LifeStance Health Group has a GF Score™ of 54/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's NonCurrent Deferred Revenue compare to CON and BKD?
LifeStance Health Group's NonCurrent Deferred Revenue of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Healthcare Providers & Services company?
A good NonCurrent Deferred Revenue depends on the Healthcare Providers & Services industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on LifeStance Health Group and its competitors. LifeStance Health Group's current NonCurrent Deferred Revenue is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.46, compared to a current price of $10.83 — trading 28% above its estimated fair value. The current NonCurrent Deferred Revenue is $0 Mil. LifeStance Health Group's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current NonCurrent Deferred Revenue is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LifeStance Health Group (LFST) Overvalued in 2026?

Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued. The current stock price of $10.83 is trading 28% above its estimated GF Value™ of $8.46. GuruFocus considers LifeStance Health Group to be Modestly Overvalued.

Key valuation signals for LFST:

  • NonCurrent Deferred Revenue: $0 Mil
  • GF Value™: $8.46 vs. price of $10.83 (28% above fair value)
  • GF Score™: 54/100 with 5 warning signs

No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LifeStance Health Group Business Description

Address 4800 North Scottsdale Road, Suite 2500, Scottsdale, AZ, USA, 85251
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
54GF Score

Get the complete analysis for LFST

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.83
Price
$8.46
GF Value